^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS exon 12 mutation

    i
    Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    5ms
    Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas (clinicaltrials.gov)
    P2, N=34, Recruiting, David E Gerber | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    KRAS mutation • EGFR mutation • ALK rearrangement • KRAS exon 2 mutation • KRAS exon 12 mutation
    |
    denifanstat (TVB-2640)
    12ms
    Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas (clinicaltrials.gov)
    P2, N=34, Recruiting, David E Gerber | N=12 --> 34
    Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    KRAS mutation • EGFR mutation • ALK rearrangement • KRAS exon 2 mutation • KRAS exon 12 mutation
    |
    denifanstat (TVB-2640)
    1year
    Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations. (PubMed, J Biomol Struct Dyn)
    The detailed analysis revealed that newly designed peptides have the potential to inhibit KRAS/Raf interaction and the oncogenic signal of the KRAS G12D mutant. Our findings strongly suggest that these peptides should be tested and clinically validated to combat the oncogenic activity of KRAS.Communicated by Ramaswamy H. Sarma.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • KRAS G12D • RAS mutation • HRAS mutation • NRAS G12D • KRAS exon 12 mutation
    over1year
    Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas (clinicaltrials.gov)
    P2, N=12, Recruiting, David E Gerber | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    KRAS mutation • EGFR mutation • ALK rearrangement • KRAS exon 2 mutation • KRAS exon 12 mutation
    |
    denifanstat (TVB-2640)
    2years
    Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas (clinicaltrials.gov)
    P2, N=12, Recruiting, David E Gerber | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    KRAS mutation • EGFR mutation • ALK rearrangement • KRAS exon 2 mutation • KRAS exon 12 mutation
    |
    denifanstat (TVB-2640)
    over3years
    Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas (clinicaltrials.gov)
    P2, N=12, Recruiting, David E Gerber | Trial completion date: Jul 2021 --> Dec 2022 | Trial primary completion date: Aug 2020 --> Dec 2021
    Clinical • Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    KRAS mutation • EGFR mutation • ALK rearrangement • KRAS exon 2 mutation • KRAS exon 12 mutation
    |
    denifanstat (TVB-2640)